Your 25-second video preview has ended.
to continue watching, please Log In or Register:
Advances in Psoriasis Treatment: IL-17 Inhibitors
Jeffery Weinberg, MD sits down with host Josh Zeichner, MD to discuss what he describes as a second revolution in the biologic therapy to treat psoriasis. Specifically, he discusses the effectiveness of a new class of biologics, IL-17 inhibitors, including first-in-class secukinumab and the recently approved ixekizumab, as well as brodalumab, which is expected to be approved soon. Dr. Weinberg discusses efficacy, dosing, patient selection, and safety profiles.